Keywords: IPOs, Financing, Life sciences, Burrill & Co

Recent therapeutics IPOs outperform, but life sciences offerings a mixed bag, says Burrill

Article | 10 September 2012

Therapeutics companies that have gone public since 2011 are up 27.1 percent as of the end of August 2012, outperforming the average 8.6% return ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in